

References

- Abhinand, C. S., Raju, R., Soumya, S. J., Arya, P. S., & Sudhakaran, P. R. (2016). VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis. *Journal of Cell Communication and Signaling*, 10(4), 347–354. <https://doi.org/10.1007/s12079-016-0352-8>
- Aghebati-Maleki, A., Dolati, S., Ahmadi, M., Baghbanzhadeh, A., Asadi, M., Fotouhi, A., Yousefi, M., & Aghebati-Maleki, L. (2019). Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers. *Journal of Cellular Physiology*, 235(3), 1962–1972. <https://doi.org/10.1002/jcp.29126>
- Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., Al-Ghamdi, H. S., Shomali, N., Zamani, A., Mohammadi, A., & Dadashpour, M. (2022). Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. *Cell Communication and Signaling*, 20(1), 49. <https://doi.org/10.1186/s12964-022-00838-y>
- Carpentier, G., Berndt, S., Ferratge, S., Rasband, W., Cuendet, M., Uzan, G., & Albanese, P. (2020). Angiogenesis Analyzer for ImageJ — A comparative morphometric analysis of “Endothelial Tube Formation Assay” and “Fibrin Bead Assay.” *Scientific Reports*, 10(1), 11568. <https://doi.org/10.1038/s41598-020-67289-8>
- Cheng, H., Chen, Y., Wong, J., Weng, C., Chen, H., Yu, S., Chen, H., Yuan, A., & Chen, J. J. (2017). Cancer cells increase endothelial cell tube formation and survival by activating the PI3K/Akt signalling pathway. *Journal of Experimental & Clinical Cancer Research*, 36(1). <https://doi.org/10.1186/s13046-017-0495-3>
- Cui, J., Cao, C., Hu, H., Zhang, H., Yang, Y., Wang, L., Huang, X., & Li, P. (2020). Downregulation of folate receptor α contributes to homocysteine-induced human umbilical vein endothelial cell injury via activation of endoplasmic reticulum stress. *Molecular Medicine Reports*, 22(2), 1631–1638. <https://doi.org/10.3892/mmr.2020.11204>

- Dadwal, A., Baldi, A., & Narang, R. K. (2018). Nanoparticles as carriers for drug delivery in cancer. *Artificial Cells Nanomedicine and Biotechnology*, 46(sup2), 295–305. <https://doi.org/10.1080/21691401.2018.1457039>
- Dash, B. S., Lai, Y., & Chen, J. (2025). Folic Acid-Conjugated magnetic Oleoyl-Chitosan nanoparticles for controlled release of doxorubicin in cancer therapy. *Nanomaterials*, 15(6), 415. <https://doi.org/10.3390/nano15060415>
- Del Pilar Rodriguez-Torres, M., Acosta-Torres, L. S., & Diaz-Torres, L. A. (2018). Heparin-Based Nanoparticles: An Overview of their applications. *Journal of Nanomaterials*, 2018, 1–8. <https://doi.org/10.1155/2018/9780489>
- Dudley, A. C., & Griffioen, A. W. (2023). Pathological angiogenesis: mechanisms and therapeutic strategies. *Angiogenesis*, 26(3), 313–347. <https://doi.org/10.1007/s10456-023-09876-7>
- García-Caballero, M., Sokol, L., Cuypers, A., & Carmeliet, P. (2022). Metabolic reprogramming in tumor endothelial cells. *International Journal of Molecular Sciences*, 23(19), 11052. <https://doi.org/10.3390/ijms231911052>
- Geindreau, M., Bruchard, M., & Vegran, F. (2022). Role of cytokines and chemokines in angiogenesis in a tumor context. *Cancers*, 14(10), 2446. <https://doi.org/10.3390/cancers14102446>
- Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023). The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. *European Journal of Pharmacology*, 949, 175586. <https://doi.org/10.1016/j.ejphar.2023.175586>
- Ghazal, H., Waqar, A., Yaseen, F., Shahid, M., Sultana, M., Tariq, M., Bashir, M. K., Tahseen, H., Raza, T., & Ahmad, F. (2024). Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment. *Next Materials*, 2, 100128. <https://doi.org/10.1016/j.nxmte.2024.100128>
- Goradel, N. H., Ghiyami-Hour, F., Jahangiri, S., Negahdari, B., Sahebkar, A., Masoudifar, A., & Mirzaei, H. (2017). Nanoparticles as new tools for inhibition of cancer angiogenesis. *Journal of Cellular Physiology*, 233(4), 2902–2910. <https://doi.org/10.1002/jcp.26029>

- Han, Y., Zhu, B., & Meng, S. (2025). Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication. *Genes & Diseases*, 12(6), 101611. <https://doi.org/10.1016/j.gendis.2025.101611>
- Hanahan, D. (2026). Hallmarks of cancer—Then and now, and beyond. *Cell*, 189(8), 2254–2277. <https://doi.org/10.1016/j.cell.2025.12.049>
- He, Y., Wang, X., Lu, W., Zhang, D., Huang, L., Luo, Y., Xiong, L., Li, H., Zhang, P., Li, Q., & Liang, S. (2022). PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. *Cell Death and Disease*, 13(2), 118. <https://doi.org/10.1038/s41419-022-04576-4>
- Heyden, K. E., Malysheva, O. V., MacFarlane, A. J., Brody, L. C., & Field, M. S. (2024). Excess Folic Acid Exposure Increases Uracil Misincorporation into DNA in a Tissue-Specific Manner in a Mouse Model of Reduced Methionine Synthase Expression. *Journal of Nutrition*, 154(11), 3225–3234. <https://doi.org/10.1016/j.tjnut.2024.09.021>
- Ibrahim, M. a. I., Othman, R., Chee, C. F., & Fisol, F. A. (2023). Evaluation of Folate-Functionalized Nanoparticle Drug Delivery Systems—Effectiveness and Concerns. *Biomedicines*, 11(7), 2080. <https://doi.org/10.3390/biomedicines11072080>
- Izadpanah, R., Izadpanah, A., & Alt, E. U. (2025). Dual faces of angiogenesis: Mechanisms and therapeutic applications. *Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer*, 1880(6), 189494. <https://doi.org/10.1016/j.bbcan.2025.189494>
- Kemp, M. M., & Linhardt, R. J. (2009). Heparin-based nanoparticles. *Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology*, 2(1), 77–87. <https://doi.org/10.1002/wnan.68>
- Koirala, N., Poudel, M., Shrivastava, A. K., Subba, R. K., Panthi, M., Paudel, S., Almarhoon, Z. M., Sharifi-Rad, J., & Calina, D. (2025). Multifaceted role of heparin in oncology: from anticoagulation to anticancer mechanisms and clinical implications. *Discover Oncology*, 16(1), 231. <https://doi.org/10.1007/s12672-025-01985-7>

- Lee, C., Kim, M., Kumar, A., Lee, H., Yang, Y., & Kim, Y. (2025). Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. *Signal Transduction and Targeted Therapy*, 10(1), 170. <https://doi.org/10.1038/s41392-025-02249-0>
- Li, J., Li, X., & Li, C. (2023). Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney. *The American Journal of the Medical Sciences*, 366(6), 404–412. <https://doi.org/10.1016/j.amjms.2023.09.005>
- Li, X., Xu, M., Shen, J., Li, Y., Lin, S., Zhu, M., Pang, Q., Tan, X., & Tang, J. (2022). Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF- κ B/AP-1 pathway and TLR4 expression. *Cell Death Discovery*, 8(1), 281. <https://doi.org/10.1038/s41420-022-01073-7>
- Li, T., Wu, J., Yu, W., Mao, Q., Cheng, H., Zhang, X., Li, Y., Li, C., Ding, Z., & Liu, L. (2022). HSPA12A Stimulates p38/ERK-AP-1 Signaling to Promote Angiogenesis and Is Required for Functional Recovery Postmyocardial Infarction. *Oxidative Medicine and Cellular Longevity*, 2022(1), 2333848. <https://doi.org/10.1155/2022/2333848>
- Liu, X., Zhang, J., Yi, T., Li, H., Tang, X., Liu, D., Wu, D., & Li, Y. (2025). Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies. *Biomarker Research*, 13(1), 62. <https://doi.org/10.1186/s40364-025-00779-x>
- Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023). Angiogenic signaling pathways and anti-angiogenic therapy for cancer. *Signal Transduction and Targeted Therapy*, 8(1), 198. <https://doi.org/10.1038/s41392-023-01460-1>
- Loizzi, V., Del Vecchio, V., Gargano, G., De Liso, M., Kardashi, A., Naglieri, E., Resta, L., Cicinelli, E., & Cormio, G. (2017). Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. *International Journal of Molecular Sciences*, 18(9), 1967. <https://doi.org/10.3390/ijms18091967>

- Lugano, R., Ramachandran, M., & Dimberg, A. (2019). Tumor angiogenesis: causes, consequences, challenges and opportunities. *Cellular and Molecular Life Sciences*, 77(9), 1745–1770. <https://doi.org/10.1007/s00018-019-03351-7>
- Mabeta, P., & Steenkamp, V. (2022). The VEGF/VEGFR Axis revisited: Implications for Cancer therapy. *International Journal of Molecular Sciences*, 23(24), 15585. <https://doi.org/10.3390/ijms232415585>
- Mahaki, H., Nobari, S., Tanzadehpanah, H., Babaeizad, A., Kazemzadeh, G., Mehrabzadeh, M., Valipour, A., Yazdinezhad, N., Manoochehri, H., Yang, P., & Sheykhasan, M. (2025). Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights. *Biomedicine & Pharmacotherapy*, 186, 118023. <https://doi.org/10.1016/j.biopha.2025.118023>
- Mukherjee, S., & Patra, C. R. (2016). Therapeutic application of anti-angiogenic nanomaterials in cancers. *Nanoscale*, 8(25), 12444–12470. <https://doi.org/10.1039/c5nr07887c>
- Nurunnabi, M., Khatun, Z., Moon, W.-C., Lee, G., & Lee, Y.-K. (2012). Heparin based nanoparticles for cancer targeting and noninvasive imaging. *Quantitative Imaging in Medicine and Surgery*, 2(3), 219–226. <https://doi.org/10.3978/j.issn.2223-4292.2012.09.01>
- Parvathaneni, V., Shukla, S. K., & Gupta, V. (2023). Development and characterization of folic Acid-Conjugated Amodiaquine-Loaded Nanoparticles–Efficacy in cancer Treatment. *Pharmaceutics*, 15(3), 1001. <https://doi.org/10.3390/pharmaceutics15031001>
- Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2022). Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. *Clinical Cancer Research*, 29(1), 30–39. <https://doi.org/10.1158/1078-0432.ccr-22-1366>
- Pieroth, R., Paver, S., Day, S., & Lammersfeld, C. (2018). Folate and its impact on cancer risk. *Current Nutrition Reports*, 7(3), 70–84. <https://doi.org/10.1007/s13668-018-0237-y>
- Rajabi, M., & Mousa, S. (2017). The role of angiogenesis in cancer treatment. *Biomedicines*, 5(2), 34. <https://doi.org/10.3390/biomedicines5020034>

- Rashidi, N., Davidson, M., Apostolopoulos, V., & Nurgali, K. (2024). Nanoparticles in cancer diagnosis and treatment: Progress, challenges, and opportunities. *Journal of Drug Delivery Science and Technology*, 95, 105599. <https://doi.org/10.1016/j.jddst.2024.105599>
- Roskoski, R. (2025). Vascular endothelial cells and angiogenesis. *Pharmacological Research*, 221, 107983. <https://doi.org/10.1016/j.phrs.2025.107983>
- Saeed, B. A., Lim, V., Yusof, N. A., Khor, K. Z., Rahman, H. S., & Samad, N. A. (2019). <p>Antiangiogenic properties of nanoparticles: a systematic review</p> *International Journal of Nanomedicine*, Volume 14, 5135–5146. <https://doi.org/10.2147/ijn.s199974>
- Satarzadeh, N., Riahi-Madvar, S., Shakibaie, M., Adeli-Sardou, M., Forootanfar, H., & Morouei, F. J. (2025). Microwave assisted synthesis and bioactive potential of folic acid functionalized tellurium nanoparticles (FA@Te NPs) against HeLa cancer cells. *Scientific Reports*, 16(1), 2314. <https://doi.org/10.1038/s41598-025-32095-7>
- Sell, M., Lopes, A. R., Escudeiro, M., Esteves, B., Monteiro, A. R., Trindade, T., & Cruz-Lopes, L. (2023). Application of Nanoparticles in cancer treatment: A Concise review. *Nanomaterials*, 13(21), 2887. <https://doi.org/10.3390/nano13212887>
- Shaw, P., Dwivedi, S. K. D., Bhattacharya, R., Mukherjee, P., & Rao, G. (2024). VEGF signaling: Role in angiogenesis and beyond. *Biochimica Et Biophysica Acta (BBA) - Reviews on Cancer*, 1879(2), 189079. <https://doi.org/10.1016/j.bbcan.2024.189079>
- Shi, Z., Kuai, M., Li, B., Akowuah, C. F., Wang, Z., Pan, Y., Tang, M., Yang, X., & Lü, P. (2025). The role of VEGF in Cancer angiogenesis and tumorigenesis: Insights for anti-VEGF therapy. *Cytokine*, 189, 156908. <https://doi.org/10.1016/j.cyto.2025.156908>
- Shizukuda, Y., Tang, S., Yokota, R., & Ware, J. A. (1999). Vascular endothelial growth Factor–Induced endothelial cell migration and proliferation depend on a Nitric Oxide–Mediated decrease in protein kinase C α activity. *Circulation Research*, 85(3), 247–256. <https://doi.org/10.1161/01.res.85.3.247>

- Song, Y., Liang, D., Liu, D., Lin, L., Zhang, L., & Yang, W. (2023). The role of the ERK signaling pathway in promoting angiogenesis for treating ischemic diseases. *Frontiers in Cell and Developmental Biology*, 11, 1164166. <https://doi.org/10.3389/fcell.2023.1164166>
- Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y., & Cai, L. (2023). Smart nanoparticles for cancer therapy. *Signal Transduction and Targeted Therapy*, 8(1), 418. <https://doi.org/10.1038/s41392-023-01642-x>
- Thabet, R. H., Alessa, R. E. M., Al-Smadi, Z. K. K., Alshatnawi, B. S. G., Amayreh, B. M. I., Al-Dwaaghreh, R. B. A., & Salah, S. K. A. (2024). Folic acid: friend or foe in cancer therapy. *Journal of International Medical Research*, 52(1), 3000605231223064. <https://doi.org/10.1177/03000605231223064>
- Wang, J., Ma, D., Lu, Q., Wu, S., Lee, G. Y., Lane, L. A., Li, B., Quan, L., Wang, Y., & Nie, S. (2015). An unusual role of folate in the self-assembly of heparin–folate conjugates into nanoparticles. *Nanoscale*, 7(37), 15185–15190. <https://doi.org/10.1039/c5nr03303a>
- Wang, X., Li, J., Wang, Y., Koenig, L., Gjyzezi, A., Giannakakou, P., Shin, E. H., Tighiouart, M., Chen, Z., Nie, S., & Shin, D. M. (2011). A Folate Receptor-Targeting nanoparticle minimizes drug resistance in a human cancer model. *ACS Nano*, 5(8), 6184–6194. <https://doi.org/10.1021/nn200739q>
- Wu, S., Hong, Y., Li, H., Lin, M., Lin, X., Lin, X., Lin, X., Lin, X., Lin, X., & Lin, X. (2025). SHBS mitigates Sorafenib-Induced apoptosis in hepatocellular carcinoma via activation of RAF1/MEK/ERK signaling pathway. *Cancer Science*, 116(9), 2471–2485. <https://doi.org/10.1111/cas.70132>
- Yang, S., Fang, Y., Ma, Y., Wang, F., Wang, Y., Jia, J., Yang, Y., Sun, W., Zhou, Q., & Li, Z. (2025). Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practice. *Clinical and Translational Medicine*, 15(4), e70313. <https://doi.org/10.1002/ctm2.70313>

- Yang, X., Du, H., Liu, J., & Zhai, G. (2014). Advanced nanocarriers based on heparin and its derivatives for cancer management. *Biomacromolecules*, 16(2), 423–436. <https://doi.org/10.1021/bm501532e>
- Yang, Y., & Cao, Y. (2022). The impact of VEGF on cancer metastasis and systemic disease. *Seminars in Cancer Biology*, 86(Pt 3), 251–261. <https://doi.org/10.1016/j.semcan.2022.03.011>
- Zhang, J., Zhan, B., Du, Y., Liu, N., Liu, S., & Li, X. (2025). Targeted cancer treatment using folic acid-functionalized carbohydrate polymers: A new era in nanomedicine. *Industrial Crops and Products*, 235, 121704. <https://doi.org/10.1016/j.indcrop.2025.121704>
- Zhang, Y., & Brekken, R. A. (2022). Direct and indirect regulation of the tumor immune microenvironment by VEGF. *Journal of Leukocyte Biology*, 111(6), 1269–1286. <https://doi.org/10.1002/jlb.5ru0222-082r>
- Zhao, W., Sachsenmeier, K., Zhang, L., Sult, E., Hollingsworth, R. E., & Yang, H. (2014). A new Bliss independence model to analyze drug combination data. *SLAS DISCOVERY*, 19(5), 817–821. <https://doi.org/10.1177/1087057114521867>